NO20071924L - Vaksiner mot japansk ecefalittvirus og West Nile virus - Google Patents
Vaksiner mot japansk ecefalittvirus og West Nile virusInfo
- Publication number
- NO20071924L NO20071924L NO20071924A NO20071924A NO20071924L NO 20071924 L NO20071924 L NO 20071924L NO 20071924 A NO20071924 A NO 20071924A NO 20071924 A NO20071924 A NO 20071924A NO 20071924 L NO20071924 L NO 20071924L
- Authority
- NO
- Norway
- Prior art keywords
- virus
- ecephalitis
- west nile
- vaccines against
- against japanese
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Det beskrives vaksiner av svekkede Flavivirus, så som vaksiner mot japansk encefalittvirus og West Nile virus, så vel som fremgangsmåter for fremstilling og anvendelse av disse vaksinene.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62046604P | 2004-10-20 | 2004-10-20 | |
US62094804P | 2004-10-21 | 2004-10-21 | |
US67441505P | 2005-04-24 | 2005-04-24 | |
US67454605P | 2005-04-25 | 2005-04-25 | |
US71892305P | 2005-09-19 | 2005-09-19 | |
PCT/US2005/037369 WO2006044857A2 (en) | 2004-10-20 | 2005-10-19 | Vaccines against japanese encephalitis virus and west nile virus |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20071924L true NO20071924L (no) | 2007-07-17 |
Family
ID=36203650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20071924A NO20071924L (no) | 2004-10-20 | 2007-04-16 | Vaksiner mot japansk ecefalittvirus og West Nile virus |
Country Status (14)
Country | Link |
---|---|
US (2) | US8029802B2 (no) |
EP (1) | EP1809325B1 (no) |
JP (1) | JP4993301B2 (no) |
KR (1) | KR101501162B1 (no) |
AU (1) | AU2005295438B2 (no) |
CA (1) | CA2584228C (no) |
EA (1) | EA015907B1 (no) |
HK (1) | HK1106723A1 (no) |
IL (1) | IL182453A0 (no) |
MY (1) | MY148075A (no) |
NO (1) | NO20071924L (no) |
NZ (1) | NZ584079A (no) |
SG (1) | SG156666A1 (no) |
WO (1) | WO2006044857A2 (no) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2439724T3 (es) | 2001-06-01 | 2014-01-24 | Sanofi Pasteur Biologics, Llc | Vectores de flavivirus quiméricos |
KR101194818B1 (ko) | 2002-01-15 | 2012-10-25 | 사노피 파스테르 바이오로직스, 엘엘씨 | 플라비바이러스 백신 |
WO2004045529A2 (en) | 2002-11-15 | 2004-06-03 | Acambis, Inc. | West nile virus vaccine |
CA2584228C (en) | 2004-10-20 | 2015-05-05 | Acambis Inc. | Vaccines against japanese encephalitis virus and west nile virus |
CN103031279B (zh) | 2005-04-24 | 2015-11-18 | 赛诺菲巴斯德生物制药有限责任公司 | 重组黄病毒疫苗 |
AU2013204985B2 (en) * | 2005-04-24 | 2016-01-28 | Sanofi Pasteur Biologics, Llc | Recombinant flavivirus vaccines |
AU2007303608B2 (en) | 2006-09-29 | 2013-05-02 | Takeda Vaccines, Inc. | Norovirus vaccine formulations |
EP2851087B1 (en) | 2006-11-07 | 2017-04-19 | Sanofi Pasteur Biologics, LLC | Stabilization of vaccines by lyophilization |
EP2117589A4 (en) * | 2007-01-31 | 2010-07-21 | Sanofi Pasteur Biologics Co | FLAVIVIRUS VACCINE VECTOR AGAINST INFLUENZA VIRUS |
JP2010539192A (ja) | 2007-09-18 | 2010-12-16 | リゴサイト ファーマスーティカルズ,インコーポレイテッド | ノロウイルスに対して防御免疫応答を付与する方法 |
US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
BRPI0913012B1 (pt) * | 2008-04-30 | 2021-12-14 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Quimera de ácido nucleico, métodos para detectar um anticorpo do vírus da dengue em uma amostra de um paciente, e para produzir partículas virais que expressam proteínas prm e e do vírus da dengue, uso de vírus codificado pela quimera e flavivírus ou partícula viral quiméricos |
AU2009279456B2 (en) | 2008-08-08 | 2015-02-05 | Takeda Vaccines, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
EP2358733B1 (en) * | 2008-11-17 | 2015-07-08 | Inovio Pharmaceuticals, Inc. | Antigens that elicit immune response against flavivirus and methods of using same |
NZ618158A (en) * | 2009-06-01 | 2015-05-29 | Takeda Vaccines Inc | Compositions and methods for administration of vaccines against dengue virus |
US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
CA2973863C (en) * | 2009-07-31 | 2022-05-17 | Ge Healthcare Bio-Sciences Corp. | High yield yellow fever virus strain with increased propagation in cells |
EP2550292B1 (en) * | 2010-03-24 | 2017-11-22 | Research Development Foundation | Flavivirus host range mutations and uses thereof |
CN101926989A (zh) * | 2010-06-29 | 2010-12-29 | 西北农林科技大学 | 表达jev免疫原基因的重组减毒鼠伤寒沙门氏菌载体疫苗及其制备方法 |
WO2012003320A2 (en) * | 2010-07-01 | 2012-01-05 | Research Development Foundation | Flavivirus host-range mutations and uses thereof |
ES2656527T3 (es) | 2011-07-11 | 2018-02-27 | Takeda Vaccines, Inc. | Formulaciones parenterales de vacunas de norovirus |
US9267114B2 (en) * | 2012-11-07 | 2016-02-23 | Southern Research Institute | Flavivirus envelope protein mutations affecting virion disassembly |
CA2933472A1 (en) | 2012-12-14 | 2014-06-19 | Takeda Vaccines, Inc. | Compositions, methods of administration and uses for trivalent dengue virus formulations |
AU2014281713A1 (en) | 2013-06-21 | 2015-11-12 | Merck Sharp & Dohme Corp. | Dengue virus vaccine compositions and methods of use thereof |
CN105473603B (zh) * | 2013-06-26 | 2019-10-25 | 北卡罗来纳-查佩尔山大学 | 用于登革病毒疫苗的方法与组合物 |
WO2016079560A1 (en) | 2014-11-21 | 2016-05-26 | Institut Pasteur | A live and attenuated japanese encephalitis virus comprising a mutated m protein |
CN106999568A (zh) | 2014-12-22 | 2017-08-01 | 默沙东公司 | 登革病毒疫苗组合物及其使用方法 |
AU2016291836A1 (en) * | 2015-07-16 | 2018-03-08 | Bharat Biotech International Limited | Vaccine compositions |
EP3947655A1 (en) * | 2019-03-28 | 2022-02-09 | Institut Pasteur | A live and attenuated flavivirus comprising a mutated m protein |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173418A (en) | 1985-05-10 | 1992-12-22 | Benzon Pharma, A/S | Production in Escherichia coli of extracellular Serratia spp. hydrolases |
US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
US6676936B1 (en) * | 1988-07-14 | 2004-01-13 | The United States Of America As Represented By The Department Of Health And Human Services. | Chimeric and/or growth-restricted flaviviruses |
DE69830579T2 (de) * | 1997-02-28 | 2006-05-04 | Acambis, Inc., Cambridge | Chimäre impfstoffe gegen flaviviren |
US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
US6589533B1 (en) | 1997-09-18 | 2003-07-08 | Research Development Foundation | Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype |
ATE314476T1 (de) | 1997-10-08 | 2006-01-15 | Us Gov Health & Human Serv | Chimärer impfstoff gegen das zeckenenzephalitis virus |
US7227011B2 (en) * | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
AU1813901A (en) | 1999-12-01 | 2001-06-12 | Oravax, Inc | Chimeric flavivirus vaccines |
WO2002081753A1 (en) | 2001-04-04 | 2002-10-17 | Advanced Research & Technology Institute | Method for identifying and characterizing individual dna molecules |
KR101194818B1 (ko) | 2002-01-15 | 2012-10-25 | 사노피 파스테르 바이오로직스, 엘엘씨 | 플라비바이러스 백신 |
AU2003205169A1 (en) | 2002-01-15 | 2003-07-30 | Acambis, Inc. | Viral vaccine production method |
US20050002968A1 (en) | 2002-01-15 | 2005-01-06 | Monath Thomas P. | Flavivirus vaccines |
WO2004045529A2 (en) * | 2002-11-15 | 2004-06-03 | Acambis, Inc. | West nile virus vaccine |
US7189403B2 (en) * | 2003-06-30 | 2007-03-13 | Institut Pasteur | Attenuated flavivirus strains containing a mutated M-ectodomain and their applications |
CA2584228C (en) | 2004-10-20 | 2015-05-05 | Acambis Inc. | Vaccines against japanese encephalitis virus and west nile virus |
CN103031279B (zh) | 2005-04-24 | 2015-11-18 | 赛诺菲巴斯德生物制药有限责任公司 | 重组黄病毒疫苗 |
-
2005
- 2005-10-19 CA CA2584228A patent/CA2584228C/en active Active
- 2005-10-19 AU AU2005295438A patent/AU2005295438B2/en active Active
- 2005-10-19 NZ NZ584079A patent/NZ584079A/en unknown
- 2005-10-19 EP EP05811861.3A patent/EP1809325B1/en active Active
- 2005-10-19 WO PCT/US2005/037369 patent/WO2006044857A2/en active Application Filing
- 2005-10-19 US US11/577,569 patent/US8029802B2/en active Active
- 2005-10-19 JP JP2007537962A patent/JP4993301B2/ja active Active
- 2005-10-19 SG SG200906992-3A patent/SG156666A1/en unknown
- 2005-10-19 EA EA200700904A patent/EA015907B1/ru not_active IP Right Cessation
- 2005-10-19 KR KR1020077011389A patent/KR101501162B1/ko active IP Right Grant
- 2005-10-20 MY MYPI20054938A patent/MY148075A/en unknown
-
2007
- 2007-04-11 IL IL182453A patent/IL182453A0/en unknown
- 2007-04-16 NO NO20071924A patent/NO20071924L/no not_active Application Discontinuation
-
2008
- 2008-01-15 HK HK08100487.2A patent/HK1106723A1/xx unknown
-
2011
- 2011-10-03 US US13/251,424 patent/US8691550B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20070269458A1 (en) | 2007-11-22 |
AU2005295438A1 (en) | 2006-04-27 |
US8691550B2 (en) | 2014-04-08 |
EP1809325A2 (en) | 2007-07-25 |
JP2008520187A (ja) | 2008-06-19 |
MY148075A (en) | 2013-02-28 |
EA200700904A1 (ru) | 2007-12-28 |
US8029802B2 (en) | 2011-10-04 |
EP1809325B1 (en) | 2013-11-20 |
EP1809325A4 (en) | 2009-07-22 |
IL182453A0 (en) | 2007-07-24 |
WO2006044857A3 (en) | 2006-08-10 |
CA2584228A1 (en) | 2006-04-27 |
EA015907B1 (ru) | 2011-12-30 |
SG156666A1 (en) | 2009-11-26 |
JP4993301B2 (ja) | 2012-08-08 |
CA2584228C (en) | 2015-05-05 |
HK1106723A1 (en) | 2008-03-20 |
NZ584079A (en) | 2011-10-28 |
KR101501162B1 (ko) | 2015-03-16 |
KR20070072597A (ko) | 2007-07-04 |
WO2006044857A2 (en) | 2006-04-27 |
AU2005295438B2 (en) | 2012-07-05 |
US20120201852A1 (en) | 2012-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20071924L (no) | Vaksiner mot japansk ecefalittvirus og West Nile virus | |
DK1999129T3 (da) | Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus | |
WO2005082020A3 (en) | Flavivirus vaccines | |
TW200745120A (en) | Indolobenzazepine HCV NS5B inhibitors | |
AP2313A (en) | Inhibitors of hepatitis C virus RNA-dependent RNA ploymerase, and compositions and treatments using the same. | |
WO2006121466A3 (en) | Hcv inhibitors | |
NO20062146L (no) | Nukleosidforbindelser for behandling av virusinfeksjoner | |
DK1797281T3 (da) | Fremgangsmåde til at estimere et bruds geometri, såvel som sammensætninger og artikler anvendt dertil | |
NO20070751L (no) | Inhibitorer av HCV-replifikasjon | |
WO2004060308A3 (en) | Thiosemicarbazones as anti-virals and immunopotentiators | |
DE602006015642D1 (de) | Hcv-replikationshemmer | |
NO20055686L (no) | Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav. | |
DK1948149T4 (da) | Formulering, som omfatter metformin og vildagliptin | |
NO20073065L (no) | Injiserbare nanopartikulaere olanzapinformuleringer | |
NO20082376L (no) | Farmasoytiske sammensetninger | |
DK1792927T3 (da) | Ny blokcopolymer, micelletilberedning og anticancermiddel indeholdende samme som aktiv ingrediens | |
IL202978A0 (en) | West nile virus vaccine | |
TW200726471A (en) | Heteroaryl derivatives for treating viruses | |
WO2006121467A3 (en) | Tetrahydrocarbazole derivatives for treating flaviridae viruses | |
DK1670458T3 (da) | 1-Amino-2-oxy-substituerede tetrahydronaphthalenderivater, fremgangsmåder til fremstilling deraf og deres anvendelse som antiphlogistika | |
NO20080351L (no) | Anvendelse av sanglifehrin i HCV | |
WO2006118607A3 (en) | Hcv inhibitors with carbazole structure | |
NO20073071L (no) | Benzotiazolformuleringer og anvendelse av disse | |
WO2006029300A3 (en) | Flavivirus variants having phenotypic variation and immunogenic compositions thereof | |
DK1614426T3 (da) | Svækkede stammer af Vibrio cholerae og lyofiliserede vacciner, som indeholder disse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |